Avacta Group PLC Annual General Meeting and Shareholder Event (1053E)
28 June 2023 - 4:00PM
UK Regulatory
TIDMAVCT
RNS Number : 1053E
Avacta Group PLC
28 June 2023
28 June 2023
Avacta Group plc
("Avacta" or the "Company" and, together with its subsidiary
undertakings, the "Group")
Annual General Meeting and Shareholder Event
Avacta Group plc (AIM: AVCT), a life sciences company developing
innovative, targeted oncology drugs and powerful diagnostics, is
today holding its Annual General Meeting ("AGM") of shareholders
and, immediately following the AGM, will hold a shareholder event
comprising a business review and presentations from the senior
management teams of the Therapeutics and Diagnostics Divisions with
Q&A.
Avacta Chief Executive, Alastair Smith, will present a business
review which will outline the commercial and corporate strategy of
the Group and its divisions. The Business Update (11:00-12:00 BST)
will be simultaneously streamed live on the Investor Meet Company
("IMC") platform. Investors who already follow Avacta on IMC will
automatically be invited to join the live stream. Investors who do
not have an IMC account can sign up for free at
https://www.investormeetcompany.com/avacta-group-plc/register-investor
and then click "Add to meet" on the Avacta page in order to receive
an invitation.
A buffet lunch will be accompanied by poster presentations
covering AVA6000, AVA3996, Affimer(R) Therapeutics and the Launch
Diagnostics business will also be present at a booth. This will
provide investors with the opportunity to meet the senior
management teams.
After lunch, the Company will discuss the AVA6000 Phase 1a
clinical data that was recently presented at the Company's Science
Day and will present the Diagnostics Division strategy.
Following closing comments and a final Q&A session, the
event will end at 14:00 BST.
All presentation materials, including slide decks and posters,
are now available on the Company's website at
https://avacta.com/investors/investor-resources/ .
- Ends-
For further information from Avacta Group plc, please
contact:
Avacta Group plc Tel: +44 (0) 1904 21 7070
Alastair Smith, Chief Executive www.avacta.com
Officer
Tony Gardiner, Chief Financial Officer
Michael Vinegrad, Group Communications
Director
Stifel Nicolaus Europe Limited Tel: +44 (0) 207 710 7600
(Nomad and Broker) www.stifel.com
Nicholas Moore / Nick Adams / Samira
Essebiyea / Nick Harland / Dhiren
Suares / William Palmer-Brown
FTI Consulting (Financial Media Tel: +44(0) 203 727 1000
and IR) Avacta.LS@fticonsulting.com
Simon Conway / Alex Shaw
Zyme Communications (Trade and Tel: +44 (0)7891 477 378
Regional Media) lily.jeffery@zymecommunications.com
Lily Jeffery
About Avacta Group plc - www.avacta.com
Avacta Group plc is a life sciences company working to improve
people's health and well-being through innovative oncology drugs
and powerful diagnostics. Operating through two divisions,
Diagnostics and Therapeutics, the Group's mission is to provide
professionals and consumers with solutions that improve healthcare,
fitness and well-being.
Avacta's Therapeutics Division, a clinical stage oncology drug
innovator, is building a wholly owned pipeline of novel Affimer(R)
immunotherapies and pre|CISION(TM) tumour targeted chemotherapies.
This approach is designed to address the lack of a durable response
to current cancer immunotherapies experienced by most patients and
reduce the severe systemic toxicities caused by chemotherapies.
There are five programmes in the pipeline as well as several global
research collaborations and licensing partnerships. Avacta's lead
programme, AVA6000, is a pre|CISION(TM) tumour-targeted form of the
established chemotherapy doxorubicin. AVA6000 is in Phase I
clinical trials in patients with locally advanced or metastatic
selected solid tumours.
The Affimer(R) platform is an alternative to antibodies that has
been designed to address many of the drawbacks of antibodies which,
despite their shortcomings, currently dominate the
immuno-diagnostics and immuno-therapeutics markets.
The pre|CISION(TM) tumour targeting platform can be used to
modify a chemotherapy in order to selectively release the active
drug in tumour tissue thereby reducing the systemic exposure that
causes damage to healthy tissues. pre|CISION(TM) modified
chemotherapies are designed to reduce the side effects and improve
the overall safety and therapeutic potential of these powerful
anti-cancer treatments.
Avacta's Diagnostics Division develops and supplies a broad
range of in-vitro diagnostic (IVD) solutions. The Division is
growing rapidly through an M&A strategy to deliver a global
scale IVD business providing market leading solutions for
healthcare professionals and consumers to inform treatment and
monitor health and well-being. In October 2022, Avacta acquired
Launch Diagnostics which serves the hospital pathology laboratory
market in the UK and Europe. In May 2023, Avacta acquired Coris
Bioconcept a Belgium based lateral flow test developer and
manufacturer adding a broad range of marketed professional-use
rapid tests into the Diagnostics Division. Avacta Diagnostic's
research and development centre in Wetherby, UK uses its
proprietary Affimer(R) platform to differentiate immunodiagnostic
products to provide marketing leading performance.
To register for news alerts by email go to
www.avacta.com/investor-news-email-alerts
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCFRMFTMTBTBPJ
(END) Dow Jones Newswires
June 28, 2023 02:00 ET (06:00 GMT)
Avacta (LSE:AVCT)
Historical Stock Chart
From Apr 2024 to May 2024
Avacta (LSE:AVCT)
Historical Stock Chart
From May 2023 to May 2024
